Curetis AG Strengthens Commercial Team and Expands Distribution Network
News Mar 11, 2013
Curetis AG has announced the appointment of Helmut Hilbert as Head of Business Development and the expansion of its distribution network into Belgium and Luxembourg by closing a distribution agreement with ELITech BNL (former Lucron Bioproducts), an ELITech Group company.
In order to strengthen its global commercial operations, Curetis has hired Dr. Helmut Hilbert, formerly Associate Director Corporate Business Development at Qiagen, as Head of Business Development.
Helmut Hilbert has more than ten years of business and corporate development experience and built a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.
At Qiagen, he was responsible for scouting novel technologies as well as evaluating potential acquisition targets and investment opportunities, including contract negotiation, due diligences and post-merger integration.
Moreover, Curetis has selected ELITech BNL as its Belgian and Luxembourgian distribution partner. ELITech BNL (former Lucron Bioproducts) has a long-standing track record as a distributor of quality diagnostic products and research supplies in the Benelux.
Among others, the company supported the market entry of Cepheid into these countries.
Acquired by the global in vitro diagnostics distributor ELITech Group in 2010, ELITech BNL is part of an extensive commercial network covering France, Italy, the UK and the rest of the world.
“Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution,” said Frank Loots, General Manager of ELITech BNL.
Loots continued, “We are planning a commercial roll-out and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories.”
“With the appointment of Helmut Hilbert as Head of Business Development and the distribution agreement with ELITech, we continue our accelerated commercial development progress,” said Oliver Schacht, CEO of Curetis.
Schacht continued, “The growing awareness for the Unyvero™ System allows us to attract experienced employees and renowned corporate partners and to expand our operations. We are in the process of growing our business in the Middle East with additional placements in Dubai, Saudi Arabia and Qatar over the next couple of months. In addition, our customer order book continues to expand significantly - we currently have a waiting list of more than fifty top-tier institutions worldwide.”
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Inflammatory Biomarkers Indicating Brain Injury IdentifiedNews
Researchers at the University of Birmingham have identified inflammatory biomarkers which indicate whether the brain has suffered injury. It is hoped that the biomarkers could be used to develop a diagnostic test to rapidly detect brain injury at the scene of an incident.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018